Top Page
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
(Sydney:RMD)
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) vs. iShares MSCI Australia ETF (EWA)
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Business Overview & Revenue Model
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Earnings Call Summary
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.26B | 5.15B | 4.69B | 4.22B | 3.58B | 3.20B |
| Gross Profit | 3.16B | 3.05B | 2.66B | 2.36B | 2.02B | 1.84B |
| EBITDA | 1.87B | 1.92B | 1.53B | 1.36B | 1.18B | 1.10B |
| Net Income | 1.44B | 1.40B | 1.02B | 897.56M | 779.44M | 474.50M |
Balance Sheet | ||||||
| Total Assets | 8.31B | 8.17B | 6.87B | 6.75B | 5.10B | 4.73B |
| Cash, Cash Equivalents and Short-Term Investments | 1.38B | 1.21B | 238.36M | 227.89M | 273.71M | 295.28M |
| Total Debt | 846.35M | 851.81M | 899.21M | 1.58B | 917.55M | 793.72M |
| Total Liabilities | 2.19B | 2.21B | 2.01B | 2.62B | 1.74B | 1.84B |
| Stockholders Equity | 6.12B | 5.97B | 4.86B | 4.13B | 3.36B | 2.89B |
Cash Flow | ||||||
| Free Cash Flow | 1.76B | 1.65B | 1.29B | 559.30M | 195.11M | 619.89M |
| Operating Cash Flow | 1.88B | 1.75B | 1.40B | 693.30M | 351.15M | 736.72M |
| Investing Cash Flow | -254.77M | -200.04M | -269.78M | -1.16B | -229.92M | -158.46M |
| Financing Cash Flow | -685.77M | -606.25M | -1.12B | 422.87M | -128.36M | -764.63M |
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Technical Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Risk Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | AU$54.89B | 24.56 | 26.73% | 0.95% | 11.99% | 32.89% | |
69 Neutral | AU$21.96B | 190.61 | 50.70% | 0.24% | 31.88% | 39.10% | |
69 Neutral | AU$17.22B | 44.29 | 20.11% | 1.64% | 4.32% | 9.24% | |
64 Neutral | AU$11.07B | 20.94 | 6.32% | 4.69% | 9.44% | -0.37% | |
54 Neutral | AU$8.12B | 1,194.26 | 0.38% | 2.25% | 6.82% | -99.27% | |
53 Neutral | €33.19B | 57.11 | ― | 0.44% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Corporate Events
Resmed has scheduled the release of its financial and operational results for the second quarter of fiscal 2026 for January 29, 2026, after the close of trading on the New York Stock Exchange, followed by a management webcast to discuss the performance. The webcast, accessible exclusively via the company’s investor relations website, will provide investors and other stakeholders with detailed insight into quarterly results, with on-demand replay options available online and via phone, underscoring Resmed’s ongoing investor communication efforts and transparency around its financial and operational trajectory.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has disclosed that Chief Executive Officer and Director Michael J. Farrell intends to sell 4,991 shares of the company’s common stock on or about January 7, 2026, through Fidelity Brokerage Services LLC, under a Rule 144 filing. The shares, valued at roughly $1.24 million based on the filing’s aggregate market value, were acquired via stock options granted in November 2019 and exercised for cash, and follow Farrell’s prior open-market sales of a total of 16,020 shares in October and November 2025, signaling continued executive share disposals that may draw investor attention to insider selling activity and capital management at the company.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed director Peter C. Farrell has filed a notice of proposed sale of company securities under SEC Rule 144, disclosing his intention to sell 2,000 common shares of ResMed through broker Merrill Lynch on the New York Stock Exchange. The filing shows that the shares to be sold were acquired via stock options exercised for cash in November 2024, and also details that Farrell sold a total of 4,000 ResMed shares in two prior transactions over the past three months, indicating ongoing, structured share disposals by an insider under a pre-adopted trading plan dated August 12, 2025, which may be viewed by investors as routine insider portfolio management rather than a signal of undisclosed negative information about the company.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s Global General Counsel and Secretary, Michael J. Rider, has reported the sale of 50 shares of ResMed common stock on 2 January 2026 at a price of $241.75 per share, leaving him with beneficial ownership of 9,741 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 28 February 2025, indicating the sale was made according to a preset schedule and may help mitigate concerns about discretionary insider trading among investors and other stakeholders.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s chief financial officer, Brett Sandercock, has reported the sale of 1,000 shares of ResMed common stock on 2 January 2026 at a price of $241.75 per share, in a transaction executed under a pre-arranged Rule 10b5-1 trading plan adopted in February 2025. Following the sale, Sandercock continues to hold 86,495 ResMed shares directly, indicating that the trade represents a small portion of his overall stake and appears to be part of a structured diversification or liquidity program rather than a change in senior management’s overall alignment with shareholders.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc., whose NYSE-listed common stock is traded on the ASX via a 10:1 CHESS Depositary Interest structure under the code RMD, reported updated figures for its CDI and underlying securities on issue for December 2025. The total number of CDIs on issue over quoted securities increased slightly to 579,449,490, a net rise of 62,160 over the month, mainly due to net transfers between CDIs and common stock listed on the NYSE. The company also reported movements in its non-CDI securities, with a net decrease reflecting transfers between ASX CDIs and NYSE common stock, issuance of new shares related to employee stock options, restricted stock units and purchase plans, and ongoing share repurchases on the NYSE, indicating active capital management and routine adjustments to its cross-listed share structure.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has disclosed that company officer Brett Sandercock plans to sell 1,000 common shares on or around 2 January 2026 through Fidelity Brokerage Services LLC, with an aggregate market value of about $241,750, under a previously adopted Rule 10b5-1 trading plan dated 19 February 2025. The filing also notes that Sandercock, who acquired these shares as restricted stock vesting in November 2022 as part of his compensation, sold a total of 4,000 ResMed shares in the prior three months for gross proceeds of nearly $987,000, providing investors with additional visibility into planned insider share disposals and trading activity but representing a small fraction of the company’s roughly 146 million shares outstanding.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
An executive of ResMed Inc., officer Michael J. Rider, has filed a notice of proposed sale of company common stock under Rule 144, covering 50 shares to be sold on the NYSE through Fidelity Brokerage Services. The shares, valued at roughly $12,088 in aggregate, were acquired as restricted stock that vested in November 2023 as part of compensation, and follow a previous sale of 50 shares in December 2025, signaling a small, routine liquidity move rather than a material change in insider holdings or company operations.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s Chairman and CEO, Michael J. Farrell, reported changes in beneficial ownership of the company’s common stock. The transactions, conducted under a pre-established Rule 10b5-1 plan, involved the acquisition and subsequent sale of shares, reflecting strategic financial management by the company’s leadership. These transactions may influence investor perceptions and highlight the company’s ongoing commitment to aligning executive interests with shareholder value.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has reported a change in beneficial ownership, with Peter C. Farrell, a director and significant shareholder, disposing of 2,000 shares of common stock at a price of $251.47 per share. This transaction, conducted under a pre-established Rule 10b5-1 plan, reflects ongoing adjustments in the company’s shareholder structure, potentially impacting investor perceptions and market dynamics.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has filed a notice of proposed sale of securities under Rule 144, indicating the sale of 2,000 common shares with an aggregate market value of $502,860. The shares are to be sold by Peter C Farrell, a director of the company, and are scheduled for sale on December 3, 2025, on the NYSE. This transaction may impact the company’s stock liquidity and shareholding structure, potentially influencing investor perception and market dynamics.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has announced an update regarding its CHESS Depositary Interests (CDIs), with a net increase of 918,810 CDIs over quoted securities for November 2025. This change is attributed to net transfers between CDIs and common stock, as well as activities related to stock options, restricted stock units, and employee stock purchase plans. The company also reported a decrease in other securities, reflecting strategic adjustments in its stock management, including share repurchases on the NYSE. These movements indicate ResMed’s ongoing efforts to optimize its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has announced a proposed sale of 1,000 common shares by Brett Sandercock, an officer of the company, under Rule 144 of the Securities Act of 1933. This transaction, set to occur on December 1, 2025, follows previous sales of 3,000 shares each in September, October, and November 2025, reflecting a strategic move by the officer to liquidate a portion of his holdings. The sale is valued at approximately $244,160 and will be conducted through Fidelity Brokerage Services LLC on the NYSE, indicating a continued trend of share sales by company insiders, which could have implications for investor perceptions and market dynamics.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc has filed a Form 144 with the SEC, indicating a proposed sale of 50 shares of common stock by Officer Michael J. Rider. The shares, acquired through restricted stock vesting, are set to be sold on December 1, 2025, on the NYSE with an aggregate market value of $12,208. This filing is part of a planned transaction under Rule 10b5-1, ensuring compliance with insider trading regulations. The sale is not expected to impact the company’s operations or market position significantly, as it represents a small fraction of the total shares outstanding.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc., a company known for its medical equipment and software solutions, has reported changes in beneficial ownership involving its director, Nicole Mowad-Nassar. The transaction involved the acquisition of 1,331 stock options at a price of $250.52, which will become exercisable by November 11, 2026, or earlier depending on the company’s annual meeting schedule. This transaction reflects strategic stock management and could influence stakeholder perceptions regarding the company’s governance and future performance.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc, a company listed on the NYSE, has filed a Form 144 for the proposed sale of securities under Rule 144 of the Securities Act of 1933. The filing indicates that Jan De Witte, a director of the company, plans to sell 2,055 shares of common stock, with an aggregate market value of $524,025. The shares were acquired through restricted stock vesting, with the sale expected to occur on November 25, 2025. This transaction reflects ongoing insider trading activities and may have implications for the company’s stock liquidity and market perception.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc., a company involved in the healthcare sector, focuses on providing innovative solutions for sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions. The recent announcement highlights a change in the company’s board, as Richard Sulpizio has ceased to serve as a director following the 2025 annual meeting of stockholders. This change in leadership may impact the company’s strategic direction and governance.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported a transaction involving the acquisition of 2,710 shares of ResMed common stock, which were performance-based restricted stock units earned upon meeting specific performance metrics. This transaction reflects the company’s commitment to aligning executive compensation with performance outcomes, potentially impacting stakeholder perceptions positively by demonstrating a focus on achieving strategic goals.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has reported changes in the beneficial ownership of its common stock by its Chairman and CEO, Michael J. Farrell. The report indicates that performance-based restricted stock units granted in 2022 were earned, and a portion of these shares was disposed of to cover tax obligations. This transaction reflects the company’s ongoing commitment to aligning executive compensation with performance metrics, potentially impacting investor perceptions and stakeholder confidence in the company’s leadership and strategic direction.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. announced a change in beneficial ownership involving Peter C. Farrell, a director and significant shareholder of the company. Farrell acquired 536 shares of ResMed common stock, which were awarded as Restricted Stock Units (RSUs) that will vest in full by November 2026 or at the next annual stockholders’ meeting. This transaction reflects ongoing changes in the company’s ownership structure, potentially impacting shareholder dynamics and corporate governance.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has reported changes in beneficial ownership involving its director, Carol Burt. The transaction involved the acquisition of 1,073 shares of ResMed common stock, with the shares awarded as Restricted Stock Units that will vest in full by November 2026 or at the next annual meeting of stockholders. This transaction highlights the company’s ongoing practices in stock-based compensation, which can impact shareholder value and executive incentives.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc, a company involved in the healthcare sector, has reported a change in beneficial ownership as per a recent filing. Jan De Witte, a director and 10% owner, acquired 1,073 shares of ResMed common stock through Restricted Stock Units (RSUs), which will vest in full by November 2026 or at the next annual stockholders’ meeting. This acquisition reflects the company’s ongoing commitment to aligning its leadership’s interests with those of its shareholders, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has reported a change in beneficial ownership as Director Christopher DelOrefice acquired 1,073 shares of common stock through Restricted Stock Units (RSUs) that vest by November 2026 or at the next annual stockholders’ meeting. This transaction reflects the company’s ongoing commitment to align its leadership’s interests with shareholder value, potentially impacting the company’s governance and stakeholder confidence.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has reported a change in beneficial ownership as Harjit Gill, a director and 10% owner, acquired 1,073 shares of ResMed common stock through Restricted Stock Units (RSUs). These RSUs are set to vest in full by November 11, 2026, or at the next annual meeting of stockholders following the grant date. This transaction highlights the company’s ongoing efforts to align management interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has reported a change in beneficial ownership, with Director Desney Tan acquiring 1,073 shares of ResMed common stock through Restricted Stock Units (RSUs). These RSUs are set to vest fully by November 11, 2026, or at the next annual stockholder meeting, indicating a strategic move to align management interests with shareholder value, potentially impacting investor confidence positively.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has announced a change in beneficial ownership involving its director, Ronald Taylor, who acquired 1,073 shares of ResMed common stock. This transaction reflects a strategic move in the company’s governance and may influence its market positioning, as it involves the vesting of Restricted Stock Units (RSUs) that will fully vest by November 2026 or at the next annual stockholders’ meeting.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has announced a change in beneficial ownership as reported by Nicole Mowad-Nassar, a director and 10% owner of the company. The transaction involved the acquisition of 536 shares of ResMed common stock, which were awarded as Restricted Stock Units (RSUs) set to vest in full by November 2026 or at the next annual meeting of stockholders. This move signifies a potential increase in insider confidence and may impact stakeholder perceptions positively, reflecting ongoing commitment to the company’s growth and stability.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc’s Chief Product Officer, Justin Leong, reported a transaction involving the acquisition of 1,848 shares of common stock, as detailed in a recent Form 4 filing. This transaction reflects the vesting of performance-based restricted stock units, indicating that the company’s performance metrics were successfully met, which may positively impact stakeholder confidence in ResMed’s operational and strategic execution.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has reported a change in beneficial ownership as per a recent SEC Form 4 filing. John Hernandez, a director and significant shareholder, acquired 1,073 shares of ResMed common stock through Restricted Stock Units (RSUs), which will vest in full by November 2026 or at the next annual meeting of stockholders. This transaction reflects ongoing confidence in the company’s growth and strategic direction, potentially impacting investor sentiment positively.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has filed a registration statement on Form S-8 with the Securities and Exchange Commission to register an additional 3,000,000 shares for its 2018 Employee Stock Purchase Plan. This move is aimed at providing more opportunities for employees to purchase company stock, potentially enhancing employee engagement and aligning their interests with those of shareholders. The registration reflects ResMed’s ongoing commitment to its workforce and could have positive implications for its market positioning and stakeholder relations.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has filed a registration statement with the SEC to register an additional 2,400,000 shares for equity awards under its 2009 Incentive Award Plan. This move increases the total authorized shares for grants of equity awards to 14,337,229, reflecting the company’s commitment to incentivizing its workforce and potentially enhancing its market competitiveness.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has reported changes in beneficial ownership, with Peter C. Farrell, a significant shareholder and Chairman emeritus, executing transactions involving the company’s common stock. The transactions include the automatic exercise of stock options and a disposition for tax withholding purposes, reflecting strategic financial management and potential impacts on shareholder value.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has reported a change in beneficial ownership as per the recent SEC Form 4 filing. Director Harjit Gill disposed of a portion of ResMed common stock for tax withholding purposes related to the vesting of Restricted Stock Units. This transaction reflects routine financial management and is not expected to significantly impact the company’s operations or market positioning.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc, a company known for its medical devices and cloud-connected solutions for people with sleep apnea, chronic obstructive pulmonary disease, and other chronic diseases, has reported changes in the beneficial ownership of its common stock. The report indicates that Peter C. Farrell, a director and 10% owner, has disposed of some shares as part of a transaction under a pre-established Rule 10b5-1 plan. This transaction reflects a strategic financial decision possibly related to tax withholding obligations on vested Restricted Stock Units, which could impact the company’s stockholder dynamics and market perception.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has reported changes in beneficial ownership as per a recent SEC Form 4 filing. The company’s Chairman and CEO, Michael J. Farrell, disposed of shares to cover tax withholdings on the vesting of Restricted Stock Units granted in previous years. These transactions reflect routine administrative actions and are not expected to significantly impact the company’s operations or market positioning.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc, a company involved in the production of medical equipment, has reported changes in beneficial ownership by its director, Jan De Witte. On November 11, 2025, De Witte disposed of a portion of his common stock holdings in ResMed, with the transaction conducted under a pre-established Rule 10b5-1 plan. This move, which included a disposition for tax withholding purposes, reflects ongoing management of equity holdings by company insiders.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has announced an update regarding the foreign exchange rate for its upcoming dividend distribution to holders of CHESS Depositary Interests (CDIs) on the Australian Securities Exchange (ASX). The exchange rate has been set at 0.6529 U.S. dollars for 1.00 Australian dollar, with dividends paid in Australian currency amounting to 0.0919 Australian dollars per CDI. The default U.S. withholding tax is 30%, but it can be reduced to 15% under the U.S.-Australia tax treaty if the necessary forms are submitted. This update reflects the company’s ongoing financial operations and its commitment to maintaining transparency with its investors.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has reported changes in the beneficial ownership of its common stock by Michael J. Rider, the company’s Global General Counsel. The transactions, which occurred on November 11, 2025, involved the disposition of shares to the issuer for tax withholding on the vesting of Restricted Stock Units granted in previous years. This update reflects standard corporate governance practices and is not expected to significantly impact ResMed’s market position or stakeholder interests.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has filed a Form 144 notice for the proposed sale of 487 shares of common stock by its director, Jan De Witte. The shares, valued at approximately $121,871.75, are set to be sold on the NYSE on November 11, 2025. This transaction involves restricted stock vesting as part of compensation, and there are no reported sales of the issuer’s securities in the past three months. The filing indicates compliance with Rule 144 under the Securities Act of 1933, ensuring transparency and adherence to regulatory requirements.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has announced a proposed sale of 2,000 common shares by Peter C Farrell, a director of the company, under Rule 144 of the Securities Act of 1933. The sale, valued at approximately $504,100, is scheduled to occur on November 12, 2025, on the NYSE. This transaction reflects a routine financial decision by an insider and does not indicate any undisclosed adverse information about the company’s operations or future prospects.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s Chairman and CEO, Michael J. Farrell, reported changes in beneficial ownership, involving transactions of common stock and stock options under a pre-established Rule 10b5-1 plan. The transactions reflect strategic financial management by the executive, with implications for the company’s stock performance and stakeholder interests, as they involve the acquisition and sale of shares at specified prices.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has filed a notice of proposed sale of securities under Rule 144, indicating that Michael J. Farrell, an officer and director of the company, plans to sell 8,011 shares of common stock. The aggregate market value of these shares is approximately $2,000,773.19, with the sale expected to take place on November 7, 2025. This transaction follows previous sales by Farrell in the past three months, reflecting ongoing insider trading activities that stakeholders may need to monitor for potential impacts on stock performance and market perception.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported a change in beneficial ownership of the company’s common stock. On November 3, 2025, Sandercock acquired 2,000 shares through stock options at a price of $101.64 per share and disposed of 3,000 shares at $247.54 per share. This transaction was conducted under a Rule 10b5-1 plan, indicating a pre-planned trading strategy. The change in ownership reflects ongoing management of equity holdings by the company’s executive, which may impact investor perceptions and the company’s stock performance.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.04 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc announced a net decrease of 3,891,110 CHESS Depositary Interests (CDIs) issued over quoted securities for October 2025, attributed to net transfers between CDIs and common stock on the NYSE. Additionally, there was an increase in securities not issued as CDIs, driven by new share issues related to stock options, restricted stock units, and employee stock purchase plans, as well as share repurchases on the NYSE. This adjustment in securities reflects Resmed’s ongoing management of its capital structure and may impact its market positioning and stakeholder interests.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.04 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has filed a notice for the proposed sale of securities under Rule 144, indicating that Brett Sandercock, an officer of the company, plans to sell 3,000 shares of common stock. The aggregate market value of these shares is approximately $742,620, with the sale expected to occur on November 3, 2025. This transaction follows a previous sale of 3,000 shares by Sandercock in September 2025, which yielded gross proceeds of $812,310. The announcement reflects ongoing insider trading activities and may impact stakeholder perceptions regarding the company’s stock performance.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.04 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has filed its quarterly report for the period ending September 30, 2025, indicating compliance with the Securities Exchange Act of 1934. The report highlights the company’s financial performance and operational updates, providing stakeholders with insights into its market positioning and strategic initiatives. The filing confirms ResMed’s status as a large accelerated filer, reflecting its significant market presence and operational scale.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$51.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.